Open Access

Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans

  • Authors:
    • Jun Yong
    • Yingchun Wang
    • Shouli Xing
    • Yufang Bi
    • Ning Li
    • Shanna Zhao
  • View Affiliations

  • Published online on: April 10, 2019     https://doi.org/10.3892/etm.2019.7476
  • Pages: 4554-4560
  • Copyright: © Yong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Clinical efficacy of trimetazidine and plasmin combined with alprostadil in the treatment of lower extremity arteriosclerosis obliterans was investigated. A retrospective analysis was performed on 132 patients with lower extremity arteriosclerosis obliterans treated in Yantai Yuhuangding Hospital from March 2015 to August 2017. Among them, 68 patients were treated with trimetazidine combined with alprostadil (group A), and 64 patients were treated with plasmin combined with alprostadil (group B). Patients were administered 2 courses of treatment and observed with regard to therapeutic effects, changes in blood flow perfusion indicators (vascular peak velocity and blood flow) of the superficial femoral artery, posterior tibial artery and dorsalis pedis artery, in endothelial function, in left ankle brachial index, in pain‑free walking distance and in maximum walking distance. After treatment, the vascular peak velocity of group B patients was lower than that in group A (P<0.05), but the blood flow was higher than that in group A (P<0.05). After treatment, endothelial esterase, high‑sensitivity C‑reactive protein and circulating endothelial cell count levels after treatment were lower than those before treatment (P<0.05), but nitric oxide level was higher than that before treatment (P<0.05). After treatment, the left ankle brachial index was lower in group A of patients than that in group B (P<0.05). After treatment, the maximum walking distance was significantly higher in group A patients than that in group B (P<0.05). After treatment, the pain‑free walking distance and maximum walking distance of the two groups of patients were higher than those before treatment (P<0.05). Both trimetazidine and plasmin combined with alprostadil can effectively treat lower extremity arteriosclerosis obliterans. The former is better than the latter in improving exercise capacity, but the latter is better than the former in improving blood flow perfusion in patients.

References

1 

Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, Moneta GL, Murad MH, Powell RJ, Reed AB, et al Society for Vascular Surgery Lower Extremity Guidelines Writing Group; Society for Vascular Surgery, : Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg. 61 (Suppl):S2.S41–41S.e1. 2015. View Article : Google Scholar

2 

Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, et al: 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 69:1465–1508. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Hinchliffe RJ, Brownrigg JR, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, Reekers J, Shearman CP, Zierler RE and Schaper NC; International Working Group on the Diabetic Foot, : IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes. Diabetes Metab Res Rev. 32 (Suppl 1):37–44. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J and Norgren L: An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Comittee. Ann Vasc Dis. 8:343–357. 2015. View Article : Google Scholar : PubMed/NCBI

5 

McDermott MM: Lower extremity manifestations of peripheral artery disease: The pathophysiologic and functional implications of leg ischemia. Circ Res. 116:1540–1550. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Zhang X, Hu Y, Zeng H, Li L, Zhao J, Zhao J, Liu F, Bao Y and Jia W: Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients. Cardiovasc Diabetol. 14:322015. View Article : Google Scholar : PubMed/NCBI

7 

Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, et al ESC Scientific Document Group, : 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 39:763–816. 2018. View Article : Google Scholar : PubMed/NCBI

8 

Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, et al: Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 65:931–941. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Chu YS, Li DX, Zhang M and Jiang TM: Trimetazidine hydrochloride as a new treatment for patients with peripheral vascular disease - an exploratory trial. Eur Rev Med Pharmacol Sci. 20:188–193. 2016.PubMed/NCBI

10 

Lawall H, Pokrovsky A, Checinski P, Ratushnyuk A, Hamm G, Randerath O, Grieger F and Bentz JWG: Efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease Fontaine Stage IV: Results of a placebo controlled randomised multicentre trial (ESPECIAL). Eur J Vasc Endovasc Surg. 53:559–566. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Huang PP, Li SZ, Han MZ, Xiao ZJ, Yang RC, Qiu LG and Han ZC: Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb Haemost. 91:606–609. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Zheng GY, Zhan JH, Luo JH and Cheng X: Effect of alprostadil on wound healing of scalded rats and the mechanism. Zhonghua Shao Shang Za Zhi. 34:380–385. 2018.(In Chinese). PubMed/NCBI

13 

Stary CM, Kohin S, Samaja M, Howlett RA and Hogan MC: Trimetazidine reduces basal cytosolic Ca2+ concentration during hypoxia in single Xenopus skeletal myocytes. Exp Physiol. 88:415–421. 2003. View Article : Google Scholar : PubMed/NCBI

14 

Sun MZ, Liu S and Greenaway FT: Characterization of a fibrinolytic enzyme (ussurenase) from Agkistrodon blomhoffii ussurensis snake venom: Insights into the effects of Ca2+ on function and structure. Biochim Biophys Acta. 1764:1340–1348. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Stoner MC, Calligaro KD, Chaer RA, Dietzek AM, Farber A, Guzman RJ, Hamdan AD, Landry GJ and Yamaguchi DJ; Society for Vascular Surgery, : Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg. 64:e1–e21. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, Lüders F, Gebauer K, Roeder N, Berger K and Malyar NM: Peripheral arterial disease and critical limb ischaemia: Still poor outcomes and lack of guideline adherence. Eur Heart J. 36:932–938. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Horie T, Kimura T and Ono K: Emerging novel biomarkers for arteriosclerosis obliterans. J Atheroscler Thromb. 23:171–172. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Hoshino J, Ubara Y, Hara S, Sogawa Y, Suwabe T, Higa Y, Nakanishi S, Sawa N, Katori H, Takemoto F, et al: Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. Circ J. 71:1193–1198. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Bandinelli F, Bartoli F, Perfetto E, Del Rosso A, Moggi-Pignone A, Guiducci S, Cinelli M, Fatini C, Generini S, Gabrielli A, et al: The fibrinolytic system components are increased in systemic sclerosis and modulated by alprostadil (alpha1 ciclodestryn). Clin Exp Rheumatol. 23:671–677. 2005.PubMed/NCBI

20 

Saigawa T, Kato K, Ozawa T, Toba K, Makiyama Y, Minagawa S, Hashimoto S, Furukawa T, Nakamura Y, Hanawa H, et al: Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J. 68:1189–1193. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, Quan N, Wang L, Yang H, Guo HM, et al: The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism. 65:122–130. 2016. View Article : Google Scholar : PubMed/NCBI

22 

Rehberger-Likozar A and Šebeštjen M: Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease. Coron Artery Dis. 26:651–656. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Lacroix R, Sabatier F, Mialhe A, Basire A, Pannell R, Borghi H, Robert S, Lamy E, Plawinski L, Camoin-Jau L, et al: Activation of plasminogen into plasmin at the surface of endothelial microparticles: A mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood. 110:2432–2439. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yong, J., Wang, Y., Xing, S., Bi, Y., Li, N., & Zhao, S. (2019). Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans. Experimental and Therapeutic Medicine, 17, 4554-4560. https://doi.org/10.3892/etm.2019.7476
MLA
Yong, J., Wang, Y., Xing, S., Bi, Y., Li, N., Zhao, S."Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans". Experimental and Therapeutic Medicine 17.6 (2019): 4554-4560.
Chicago
Yong, J., Wang, Y., Xing, S., Bi, Y., Li, N., Zhao, S."Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans". Experimental and Therapeutic Medicine 17, no. 6 (2019): 4554-4560. https://doi.org/10.3892/etm.2019.7476